This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John J. DiGiovanna, MD; Harvey Blank, MD
Bldg 10, Room 12N238 Dermatology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20205; University of Miami

Arch Dermatol. 1985;121(1):21.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

As Dr Kagan has carefully noted, we failed to indicate the isometric form of lysine. The pure L-isomer of lysine hydrochloride was used in our study and we should have stated that in the original article.

Kagan states that the lysine dosage used in our study was "low." We chose this dosage because of Kagan's study, in which this was the highest dosage administered ("312-1,200 mg of lysine daily").¹ With doses of this magnitude or less, the results reported from the article were described as follows. The pain disappeared abruptly overnight in virtually every instance, new vesicles failed to appear, and resolution in the majority was considered to be more rapid than in their past experience. The most encouraging finding... was the reduction in frequency of recurrences. Taking therapeutic doses of 500-1,000 mg or increasing the maintenance dose would invariably abort recurrence.

Since our dose (1,200 mg) . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?